7:00 – 8:15
SATURDAY 18 JUNE
BREAKFAST SESSION 9
Fisher & Paykel Healthcare Breakfast Session - Respiratory management during COVID-19: What have we learnt and where to from here?
During this symposium, Dr Sanj Fernando will present his personal experience at Liverpool ED, during the Delta wave of COVID, that was primarily concentrated in South West Sydney. Following this presentation Rory Monro will discuss how in the early period of the COVID pandemic, a specialised team was created at Fisher and Paykel Healthcare to understand the impact respiratory support therapies have on the risk of infection for caregivers. This short talk is an overview of the understanding of respiratory bio-particles, alongside the latest clinical research on the relative risk of different therapies.
Chair: A/Prof Nigel Fealy CCRN, Grad Dip Ed, MN, PHD
Speakers:
Liverpool ED: COVID-19 Review, Dr Sanj Fernando, Emergency Physician; Liverpool Hospital
Cough’s and sneezes spread diseases – but do AGP’s?, Rory Monro. Senior product Development Engineer; Fisher & Paykel Healthcare

Speaker: Dr Sanj Fernando
Sanj Fernando is a senior Emergency Physician working at Liverpool Hospital and a senior retrieval / pre-Hospital Physician working with NSW Ambulance. Up until recently he was the Emergency Department Director at Liverpool Hospital. He was Director during the unprecedented acuity of the delta wave of COVID that was primarily concentrated in South West Sydney.

Speaker: Rory Monro
Rory Monro is a Senior Product Development Engineer at Fisher and Paykel Healthcare in New Zealand. He has spent much of his career designing respiratory and surgical products for hospital use. Rory graduated from the University of Auckland with an engineering degree specialising in Mechatronics, and has a Masters degree in Medical Devices and Technologies. Early in the COVID pandemic, a specialised team was created at Fisher and Paykel Healthcare to understand the impact respiratory support therapies have on the risk of infection for caregivers. This short talk will give an overview of the teams journey in understanding respiratory bio-particles, alongside the latest clinical research on the relative risk of different therapies.